Compare Merck & Co., Inc. (MRK) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nasdaq100 ETF — how do they compare? Merck & Co., Inc. trades at $145.85 (market cap $351.28B), while Nasdaq100 ETF trades at $750.53 (market cap $506.92B). The key difference: Nasdaq100 ETF is the larger of the two by market cap, and Merck & Co., Inc. pays a 2.39% dividend while Nasdaq100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Nasdaq100 ETF for 162 Days on average.
| MRK | QQQ | |
|---|---|---|
Market Cap | $351.28B | $506.92B |
Volume | 7,969,665 | 48,326,518 |
Sector | Health | — |
52-Week High | $156.43 | $759.66 |
52-Week Low | $82.49 | $558.34 |
Typical Hold Time | 98 Days | 162 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
QQQ trades at $749.24, down 1.12% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings and mixed analyst sentiment with a 50% buy/50% sell split. Recent news highlights QQQ's tech concentration and fee comparisons with competing ETFs, while broader market concerns about AI valuations and interest rates create headwinds.
The outlook remains cautiously optimistic given strong technical momentum, though elevated tech valuations and Federal Reserve policy pose risks. QQQ's innovation-focused portfolio offers growth exposure but requires monitoring of concentration risk in the technology sector amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
